Incannex Healthcare Halted, News Pending
Investing.com -- Bio-Rad Laboratories, Inc. (NYSE:BIO) reported first-quarter earnings and revenue that surpassed analyst expectations, but lowered its full-year 2025 guidance due to market uncertainties. The stock rose 1.9% following the announcement.
The life science research and clinical diagnostics company posted adjusted earnings per share of $2.54, beating the analyst estimate of $1.80 by $0.74. Revenue for the quarter came in at $585.4 million, exceeding the consensus estimate of $573.22 million but declining 4.2% YoY from $610.8 million.
Bio-Rad’s CEO Norman Schwartz commented, "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management."
The company updated its full-year 2025 outlook, now expecting non-GAAP, currency-neutral revenue to range from a 1.0% decline to 1.5% growth, down from its previous estimate of 1.5% to 3.5% growth. Bio-Rad also lowered its estimated non-GAAP operating margin to 10.0% to 12.0%, compared to its prior expectation of 13.0% to 13.5%.
Life Science segment sales decreased 5.4% to $228.6 million, while Clinical Diagnostics segment sales fell 3.2% to $356.8 million compared to the same period last year.
The company’s non-GAAP gross margin for the quarter was 53.8%, slightly down from 54.2% in the first quarter of 2024. Bio-Rad’s effective tax rate for Q1 2025 was 23.3%, up from 21.8% in the same period last year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.